New drug combo aims to fight tough head and neck cancers
NCT ID NCT06919666
Summary
This study is testing a new drug called NT219 in combination with two existing cancer drugs (pembrolizumab or cetuximab) for people with advanced head and neck cancer that has returned or spread. The main goal is to see if these combinations can shrink tumors and control the disease. Researchers will also closely monitor side effects to understand the safety of these treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UCHealth Highlands Ranch Hospital
RECRUITINGHighlands Ranch, Colorado, 80126, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Universtiy of Colorado Hospital
RECRUITINGAurora, Colorado, 80045, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.